Boehringer Ingelheim Opens AI Centre in London to Advance Drug Development
Boehringer Ingelheim has launched a new AI and machine learning centre in London, aimed at enhancing drug development processes. This centre is part of a £150 million investment over ten years to integrate AI into research and development. The London site will focus on understanding patient journeys and discovering biological mechanisms to develop targeted medicines. This initiative is expected to accelerate the development of therapies for patients with unmet medical needs. The centre will join Boehringer's existing AI-focused sites in the US, Austria, and Germany, and is expected to employ 50 AI experts by 2027. 
